Diaxonhit Share Price Euronext Paris
Equities
FR0004054427
Biotechnology & Medical Research
Sales 2023 * | 131M 140M 11.19B | Sales 2024 * | 138M 148M 11.82B | Capitalization | 146M 156M 12.51B |
---|---|---|---|---|---|
Net income 2023 * | 6M 6.42M 514M | Net income 2024 * | 9M 9.62M 771M | EV / Sales 2023 * | 1.19 x |
Net Debt 2023 * | 8.8M 9.41M 754M | Net cash position 2024 * | 9.9M 10.59M 848M | EV / Sales 2024 * | 0.99 x |
P/E ratio 2023 * |
33.2
x | P/E ratio 2024 * |
15
x | Employees | - |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 59.14% |
Managers | Title | Age | Since |
---|---|---|---|
Denis Fortier
CEO | Chief Executive Officer | - | 18/06/17 |
Director of Finance/CFO | 43 | 30/09/22 | |
Cathie Marsais
COO | Chief Operating Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Denis Fortier
CEO | Chief Executive Officer | - | 18/06/17 |
Director/Board Member | 68 | 03/11/09 | |
Director/Board Member | 67 | 14/06/17 |
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |